Acumen Pharmaceuticals Inc. (ABOS)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.72 |
Market Cap | 103.64M |
Revenue (ttm) | 290.00K |
Net Income (ttm) | -81.67M |
EPS (ttm) | -1.38 |
PE Ratio (ttm) | -1.25 |
Forward PE | -1.75 |
Analyst | Buy |
Ask | 1.73 |
Volume | 261,577 |
Avg. Volume (20D) | 312,566 |
Open | 1.72 |
Previous Close | 1.75 |
Day's Range | 1.67 - 1.77 |
52-Week Range | 1.53 - 5.09 |
Beta | 0.04 |
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia....
Analyst Forecast
According to 3 analyst ratings, the average rating for ABOS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 305.80% from the latest price.
Why Price Moved
News
2 months ago · seekingalpha.com
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call TranscriptAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2024 Results Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Braun - Head of Investor Relations Dan O'Connell - Chief Executive Of...